![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUMM Summit Therapeutics plc ("Summit Therapeutics" or the "Company") Notification of Transactions of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 January 2020, Mr Robert W. Duggan, a Non-Executive Director of the Company, sold a total of 33,321,870 ordinary shares and transferred a total of 4,998,279 warrants to various trusts as detailed below. Number of Ordinary Sale Price per Number of Warrants Name of Trust Shares Sold Ordinary Share* Transferred ------------------ ------------------ ------------------ ------------------ Daniel Douglas Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Dante Eon Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ David Michael Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Diamond Augustus Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Diana Star Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Dsara Ann Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Dylan Duke Duggan Trust 1,753,780 22.1 pence 263,067 ------------------ ------------------ ------------------ ------------------ Mahkam Zanganeh Revocable Trust 10,522,705 22.1 pence 1,578,405 ------------------ ------------------ ------------------ ------------------ Shaun Zanganeh Irrevocable Trust 10,522,705 22.1 pence 1,578,405 ------------------ ------------------ ------------------ ------------------ Total 33,321,870 4,998,279 ------------------ ------------------ ------------------ ------------------ * The sale price per ordinary share has been converted from US Dollars at an exchange rate of $1.2900 to GBP1.00. Following the completion of these dealings, Mr Duggan has the following interest in the Company's ordinary shares and warrants, respectively: % of Issued Shareholding Share Capital Warrants ----------------- ---------------- ------------ --------------- ---------- Non-Executive Robert W. Duggan Director 211,123,385 62.85% 19,925,276 ----------------- ---------------- ------------ --------------- ---------- This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson / Ludovico Lazzaretti N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / George Tzimas, Corporate Finance Tom Salvesen, Corporate Broking Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500 Phil Walker / Dominic Wilson MSL Group (US) Tel: +1 781 684 6552 mailto:summit@mslgroup.com Erin Anthoine summit@mslgroup.com ------------------------------ Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / mailto:summit@consilium-comms. Sukaina Virji / Lindsey Neville com summit@consilium-comms.com ------------------------------ The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014. 1 Details of the persons discharging managerial responsibilities/person closely associated ----------------------------------------------------------------------------- a) Name (i) Robert W. Duggan ----------------------- ---------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position / status (i) Non-Executive Director ----------------------- ---------------------------------------------------- b) Initial notification / Initial notification Amendment ----------------------- ---------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name Summit Therapeutics plc ----------------------- ---------------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 ----------------------- ---------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary shares of 1 penny each financial instrument, type of instrument Identification code GB00BN40HZ01 ----------------------- ---------------------------------------------------- b) Nature of the Sale of ordinary shares of one penny nominal value transactions ----------------------- ---------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ----------------------- --------------------------- ------------------- (i) 22.1p (exercise price) (i) 33,321,870 ----------------------- --------------------------- ------------------- d) Aggregated information - Aggregated volume 33,321,870 ordinary shares - Price 22.1 pence ----------------------- ---------------------------------------------------- e) Date of the 14 January 2020 transactions ----------------------- ---------------------------------------------------- f) Place of the Outside a trading venue transactions ----------------------- ---------------------------------------------------- 1 Details of the persons discharging managerial responsibilities/person closely associated -------------------------------------------------------------------------------------- a) Name (ii) Robert W. Duggan ------------------------- ----------------------------------------------------------- 2 Reason for the notification -------------------------------------------------------------------------------------- a) Position / status (ii) Non-Executive Director ------------------------- ----------------------------------------------------------- b) Initial notification / Initial notification Amendment ------------------------- ----------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------------------- a) Name Summit Therapeutics plc ------------------------- ----------------------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 ------------------------- ----------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 penny each financial instrument, type of instrument Identification code GB00BN40HZ01 ------------------------- ----------------------------------------------------------- b) Nature of the Transfer of warrants to subscribe for ordinary shares transactions of one penny nominal value ------------------------- ----------------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ------------------------- ---------------------- ------------------------------- (i) n/a (ii) 4,998,279 ------------------------- ---------------------- ------------------------------- d) Aggregated information - Aggregated volume 4,998,279 warrants to subscribe for ordinary shares - Price n/a ------------------------- ----------------------------------------------------------- e) Date of the transactions 14 January 2020 ------------------------- ----------------------------------------------------------- f) Place of the transactions Outside a trading venue ------------------------- ----------------------------------------------------------- -END-
(END) Dow Jones Newswires
January 15, 2020 07:15 ET (12:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions